BMJ:结直肠癌患者生存期预测:队列研究

2017-06-19 海北 MedSci原创

为了开发和验证预测结直肠癌患者绝对和条件生存率的风险方程,两位英国科学家进行了一项大规模的实验。他们招募了44,154名15-99岁的结直肠癌患者,以得到风险方程。该风险方程又在来自305个QRearch的15,214名结直肠癌患者,以及来自国家癌症中心的437,821名结直肠癌患者中得到了验证。

为了开发和验证预测结直肠癌患者绝对和条件生存率的风险方程,两位英国科学家进行了一项大规模的实验。他们招募了44,15415-99岁的结直肠癌患者,以得到风险方程。该风险方程又在来自305QRearch15,214名结直肠癌患者,以及来自国家癌症中心的437,821名结直肠癌患者中得到了验证。

该实验的主要结果是所有原因的死亡率,次要结果是结直肠癌引起的死亡率。最终得到的预测模型将患者的年龄,癌症阶段,癌症等级等多个因素列入了计算范围之中。他们发现,年龄较小,处于癌症早期,良性或中度分化癌,结直肠癌手术,肠癌家族史,他汀类药物以及阿司匹林的使用和女性患者良好的生存率挂钩。这在男性患者中也适用。

此次得到的风险方程已经经过了良好的校准,其预测到的风险和实际观察到的风险密切相关。此外,在列队研究中,没有性别的偏向性。

风险预测方程的开发和验证,能够预测结直肠癌患者的总体和条件生存率。这样的方程能够为结直肠癌患者提供更加个性化的精准信息,帮助医生进行决策以及后续的治疗。

原始出处:

Julia Hippisley-Cox et al. Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study. BMJ 2017;357:j2497. DOI: https://doi.org/10.1136/bmj.j2497

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932578, encodeId=e75319325e8b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 16 11:12:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848328, encodeId=2cab18483287c, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Oct 24 01:12:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213572, encodeId=73952135e2c6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 21 18:51:31 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378136, encodeId=f63f13e813638, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452926, encodeId=74ff14529267e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1932578, encodeId=e75319325e8b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 16 11:12:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848328, encodeId=2cab18483287c, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Oct 24 01:12:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213572, encodeId=73952135e2c6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 21 18:51:31 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378136, encodeId=f63f13e813638, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452926, encodeId=74ff14529267e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
    2017-10-24 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1932578, encodeId=e75319325e8b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 16 11:12:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848328, encodeId=2cab18483287c, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Oct 24 01:12:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213572, encodeId=73952135e2c6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 21 18:51:31 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378136, encodeId=f63f13e813638, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452926, encodeId=74ff14529267e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
    2017-06-21 luominglian113

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1932578, encodeId=e75319325e8b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 16 11:12:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848328, encodeId=2cab18483287c, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Oct 24 01:12:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213572, encodeId=73952135e2c6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 21 18:51:31 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378136, encodeId=f63f13e813638, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452926, encodeId=74ff14529267e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1932578, encodeId=e75319325e8b0, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Apr 16 11:12:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1848328, encodeId=2cab18483287c, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Oct 24 01:12:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213572, encodeId=73952135e2c6, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Jun 21 18:51:31 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378136, encodeId=f63f13e813638, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452926, encodeId=74ff14529267e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Wed Jun 21 14:12:00 CST 2017, time=2017-06-21, status=1, ipAttribution=)]

相关资讯

[重复]Crit Rev Oncol Hemat:结直肠癌肝转移后肝功受损,如何选择治疗?

继发于结直肠癌肝转移的肝功能不全预后很差,不但治疗缺少指南指导,而且治疗后发生并发症风险增高。比利时Faugeras教授在《Critical Reviews in Oncology/Hematology》杂志发文对不同化疗和靶向治疗模式进行比较,据此对结直肠癌肝转移导致肝功能不全患者的治疗选择进行了相关推荐。

结直肠癌诊治“中山模式”获国内外专家高度称赞

“11年前,是他们把我这个肠癌晚期伴肝转移的患者从死亡边缘拯救回来,才能在今日与大家一样拥有健康的体魄。现在的我心情开朗,精神抖擞,对今后的生活更充满了信心。”6月17日至19日,在一场云集来自美国、英国、法国、德国、西班牙、意大利、比利时、奥地利、韩国、日本、港澳、中国台湾以及大陆1200人次以上专家学者的国际学术论坛上,一位特殊的发言者登上了讲坛,他是来自中国70岁的严惟明先生,2006年

维生素D可减缓结直肠癌的恶化!

近年来,研究数据表明,维生素D在血浆中的含量越高,越能提高结直肠癌患者的生存率。如今,首次随机实验证明,高剂量补充维生素D可有效减缓疾病的恶化。

Crit Rev Oncol Hematol:结直肠癌肝转移后肝功受损,如何选择治疗?

结直肠癌常用化疗药物包括5-氟脲嘧啶、奥沙利铂、伊立替康,靶向药物包括贝伐单抗、阿柏西普、西妥昔单抗、帕尼单抗和瑞格非尼。肝转移导致肝功能不全的机制包括健康肝脏容积减少、肝内外胆管阻塞、门脉梗塞、癌症相关因子增加胆汁瘀积和炎症损害。与肝脏合成功能相关血清学指标包括白蛋白、PT、ALT、AST,与瘀胆相关指标包括ALP、GGT、DBIL,胆红素是严重肝损害的特异指标。那么,结直肠癌患者肝转移后肝功受

Redox Biol:IDH2或是结直肠癌重要预防因子之一

IBD是包括UC(溃疡性结肠炎)和CD(克罗恩氏病)在内的一系列具有慢性、复发性、免疫相关等特点的炎症性肠病。随着生活水平的提高,IBD已经成为一个全球性疾病。尤其是在经济快速发展的中国,患者的患病率迅速增加。 肠道癌症是IBD的后期并发症,相比于CD,UC更常见发生,而且通常更累及结肠。结肠癌风险在该疾病八年后开始增加,随着炎症程度的增加而升高,累及整个结肠的结肠炎患者更可能进展为癌症。

SCI REP:RUFY3与FOXK1的相互作用促进结直肠癌的侵袭和转移

我们的研究结果揭示了RUFY3的一种新颖的意想不到的调节功能。我们将FOXK1鉴定为新的RUFY3结合蛋白。本研究揭示了RUFY3在诱导EMT和由异常FOXK1表达引起的迁移和侵袭表型中的关键作用。因此,RUFY3-FOXK1轴可能代表治疗CRC的新靶点。